Therapeutic Solutions International, Inc. (TSOI) reported that its breast cancer immunotherapy spin-off company, Res Nova Bio, released data showing synergistic suppression of breast cancer growth when used in combination with anti-PD1 and anti-CTLA4 antibodies, which represent clinically used checkpoint inhibitors such as Keytruda and Yervoy, respectively. Additionally, the Company demonstrated that FloraStilbene?? administration increased efficacy of the standard chemotherapies Taxotere and Cytotoxan which are used in breast cancer.

The data were filed in a patent application covering adjuvant use of Flora Stilbene?? in radiotherapy, oncolytic virus therapy, adoptive cellular therapy, chimeric antigen receptor therapy, chemotherapy and immunotherapy. Studies have shown that the abortion pill reduces activity of the cytokine TGF-beta which is involved in protecting the fetus from the maternal immune response, as well as protecting cancer cells from immunity of the body.

At a cellular level immature dendritic cells, which are found in both cancer and pregnancy seem to be stimulated to maturation by treatment with the abortion pill.